Document is current
Any future updates will be listed below
-
Authors
Özlü, Serap https://orcid.org/0009-0007-3134-6580
Dyrba, Martin
Grazia, Alice
Brosseron, Frederic
Buerger, Katharina
Dechent, Peter
Düzel, Emrah
Ewers, Michael
Fliessbach, Klaus
Glanz, Wenzel
Hansen, Niels
Hellmann-Regen, Julian
Hetzer, Stefan
Janowitz, Daniel
Kilimann, Ingo
Kronmüller, Marie
Laske, Christoph
Lüsebrink, Falk
Mengel, David
Perneczky, Robert
Peters, Oliver
Priller, Josef
Ramirez, Alfredo
Rauchmann, Boris-Stephan
Rostamzadeh, Ayda
Schneider, Anja
Sodenkamp, Sebastian
Spottke, Annika
Spruth, Eike Jakob
Synofzik, Matthis
Wiltfang, Jens
Heneka, Michael T
Jessen, Frank
Teipel, Stefan
-
Funding
Funding for this research was provided by:
Deutsche Forschungsgemeinschaft (374011584/3T)
Deutsches Zentrum für Neurodegenerative Erkrankungen e.V. (DZNE) in der Helmholtz-Gemeinschaft
- License Information
-
More Information
Article History
Received: 28 August 2025
Revised: 30 November 2025
Accepted: 2 December 2025
First Online: 24 December 2025
Declarations
:
: K.B. has travel support by Lilly Germany and Novo Nordisk, as well as speaker honoraria by Eisai GmbH Germany and Lilly Germany. S.T. served on advisory boards of Lilly, Eisai, Biogen, and GE, and was a member of the independent data safety and monitoring board of the study ENVISION (Biogen).
: The study protocol was approved by the local institutional review boards and ethics committees of all participating sites and is conducted in accordance with the Declaration of Helsinki. All participants provided written informed consent prior to participation.
: Not applicable.
